The Latest Breaking News from Lilly

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Futures rose as Bitcoin rebounded. It's a bear market, so stay safe. Tesla rival BYD is among a few stocks setting up.

The ideal scenario for this Lilly stock option trade for the stock to stay between 300 and 335 for the next two weeks.

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

A newly confirmed stock market rally immediately came under heavy pressure as Walmart and Target warnings slammed the major indexes.